Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

GCT02

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Myrio Therap

Drug class:

EGFRvIII-targeted CAR-T immunotherapy

Related drugs:

‹

CARv3-TEAM-E T cells (0)

multi-target gene-modified CAR-T/TCR-T cell immunotherapy (0)

CARv3-TEAM-E T cells (0)

multi-target gene-modified CAR-T/TCR-T cell immunotherapy (0)

›

almost2years

Human EGFRvIII chimeric antigen receptor T cells demonstrate favorable safety profile and curative responses in orthotopic glioblastoma. (PubMed, Clin Transl Immunology)

Here, we show our de novo generated, high-affinity EGFRvIII-specific CAR; GCT02, demonstrating curative efficacy in human orthotopic glioblastoma models...This study demonstrates the preclinical functionality of a highly specific CAR targeting EGFRvIII on human cells. This CAR could be an effective treatment for glioblastoma and warrants future clinical investigation.

almost 2 years ago

Journal • CAR T-Cell Therapy

|

EGFR (Epidermal growth factor receptor)

|

EGFR mutation

|

GCT02